

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

SUPPLEMENTAL ANNOUNCEMENT

(1) DISCLOSEABLE TRANSACTIONS

(2) ISSUE OF NEW SHARES UNDER GENERAL MANDATE

(3) DISPOSAL OF SHARES BY A CONTROLLING SHAREHOLDER

Reference is made to the announcements of Genscript Biotech Corporation (the “**Company**”) dated 14 May 2021 in relation to, among others, the discloseable transactions (the “**First Announcement**”), the issue of new shares under general mandate (the “**Second Announcement**”), the disposal of shares by a controlling shareholder (the “**Third Announcement**”) and other related matters and clarifications (collectively, the “**Announcements**”).

DISCLOSEABLE TRANSACTIONS

Unless otherwise defined, capitalised terms used in this section of the announcement shall have the same meanings as those defined in the First Announcement.

In addition to the information provided in the First Announcement, the Board would like to inform the shareholders of the Company that, when the deemed disposal of the equity interest in Probio Cayman proceeds and a definitive agreement regarding the Term Sheet is entered into, further announcements will be made by the Company setting out the detailed terms of such deemed disposal, including among others, the basis for determining the consideration or the Original Purchase Price, and other material ancillary terms of the Series A Financing.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY AFTER THE SUBSCRIPTION AND THE DISPOSAL

Unless otherwise defined, capitalised terms used in this section of the announcement shall have the same meanings as those defined in the Second Announcement and Third Announcement.

The table below sets out a summary of the shareholding structure of the Company (i) as at the date of the Announcements; (ii) after the completion of the Subscription (assuming that the Disposal has not been completed and there is no change in the issued share capital of the Company since the date of the Announcements save for the issuance of the Subscription Shares); (iii) after completion of the Disposal (assuming that the Subscription has not been completed and there is no change in the issued share capital of the Company since the date of the Announcements); and (iv) after completion of the Subscription and the Disposal (assuming there is no change in the issued share capital of the Company since the date of the Announcements save for the issuance of the Subscription Shares):

Shareholders	As at the date of the Announcements		Following the completion of the Subscription (assuming that the Disposal has not been completed and there is no change in the issued share capital of the Company since the date of the Announcements save for the issuance of the Subscription Shares)		Following the completion of the Disposal (assuming that the Subscription has not been completed and there is no change in the issued share capital of the Company since the date of the Announcements)		Following the completion of the Subscription and the Disposal (assuming there is no change in the issued share capital of the Company since the date of the Announcements save for the issuance of the Subscription Shares)	
			Number of		Number of		Number of	
	Number of Shares held	%	Number of Shares held	%	Number of Shares held	%	Number of Shares held	%
Genscript Corporation (Note 1)	871,366,235	44.52	871,366,235	42.30	809,577,123	41.36	809,577,123	39.30
GNS Holdings Limited	—	—	102,981,853	5.00	61,789,112	3.16	164,770,965	8.00
Other shareholders	<u>1,085,790,876</u>	<u>55.48</u>	<u>1,085,790,876</u>	<u>52.70</u>	<u>1,085,790,876</u>	<u>55.48</u>	<u>1,085,790,876</u>	<u>52.70</u>
Total issued Shares	<u>1,957,157,111</u>	<u>100.00</u>	<u>2,060,138,964</u>	<u>100.00</u>	<u>1,957,157,111</u>	<u>100.00</u>	<u>2,060,138,964</u>	<u>100.00</u>

Note:

- Genscript Corporation is a company incorporated in the State of Delaware in the U.S. and owned as to approximately 37.47%, approximately 3.66%, approximately 22.76%, approximately 7.96%, approximately 2.07%, approximately 0.70%, approximately 0.42%, approximately 0.42%, approximately 11.10%, approximately 10.26%, approximately 1.95%, approximately 1.05% and approximately 0.18% by Zhang Fangliang, the Zhang Trust, Wang Luquan, Wu Yongmei, the Wu 2017 Trust, the Wu 2019 Trust, the Wu 2020 Separate Trust A, the Wu 2020 Separate Trust B, the Wu 2020 Trust, Wang Ye, the Wang Trust, Mu Yingjun and Charity B, respectively.

Save as disclosed in this announcement, all other information set out in the Announcements remain unchanged.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 7 June 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*